ArticleAmerican journal of translational research2018
Exosome-related lncRNAs as predictors of HCC patient survival: a prognostic model.
Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Dynamic role of exosomal long non-coding RNA in liver diseases: pathogenesis and diagnostic aspects.Hepatology international · 2024Review
- Extracellular Vesicle-Related Non-Coding RNAs in Hepatocellular Carcinoma: An Overview.Cancers · 2024Review
- Extracellular Vesicles in Hepatocellular Carcinoma: Progress and Challenges in the Translation from the Laboratory to Clinic.Medicina (Kaunas, Lithuania) · 2023Review
- Exosomal Long Noncoding RNAs Serve as Biomarkers for Liver Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Review
- Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer.Exploration of targeted anti-tumor therapy · 2023Review
- Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.Hepatology international · 2022Article
- An emerging role of radiation‑induced exosomes in hepatocellular carcinoma progression and radioresistance (Review).International journal of oncology · 2022Review
- Recent Advances in Device Engineering and Computational Analysis for Characterization of Cell-Released Cancer Biomarkers.Cancers · 2022Review
- Exosomal long non-coding RNAs: novel molecules in gastrointestinal cancers' progression and diagnosis.Frontiers in oncology · 2022Review
- Current Perspectives on the Unique Roles of Exosomes in Drug Resistance of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2022Review
- Identification of senescence-associated long non-coding RNAs to predict prognosis and immune microenvironment in patients with hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Development and validation of a genomic instability-related lncRNA prognostic model for hepatocellular carcinoma.Frontiers in genetics · 2022Article
- The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment.Frontiers in immunology · 2022Review
- Integrative analysis of the gastric cancer long non-coding RNA-associated competing endogenous RNA network.Oncology letters · 2021Article
- A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma.Frontiers in genetics · 2021Article
- Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma.Frontiers in oncology · 2020Article
- Screening and verification of long noncoding RNA promoter methylation sites in hepatocellular carcinoma.Cancer cell international · 2020Article
- Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells.Journal of Cancer · 2020Article
- Comprehensive analysis of five long noncoding RNAs expression as competing endogenous RNAs in regulating hepatoma carcinoma.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAccumulating evidence suggests that long non-coding RNA (lncRNA) may affect hepatocellular carcinoma (HCC) progression. However, the mechanism remains unclear. Previous studies have shown that exosomes may promote tumor progression by transporting proteins. Our study aimed to determine the prognostic value of lncRNAs in HCC and the underlying mechanism.
methodsA dataset comprising a HCC cohort of 364 patients from The Cancer Genome Atlas (TCGA) was analyzed to identify lncRNAs with prognostic value. Co-expression and competing endogenous RNA (ceRNA) networks were constructed to investigate the mechanism of exosome-related lncRNAs. To confirm the bioinformatics analysis results, 95 pairs of clinical samples were evaluated by digoxigenin-labeled chromogenic in situ hybridization (CISH).
resultsFive lncRNAs (CTD-2116N20.1, AC012074.2, RP11-538D16.2, LINC00501 and RP11-136I14.5) with significant differences were identified (P<0.001). A prognostic nomogram was constructed with a C-index of 0.701. The co-expression and ceRNA networks showed possible mechanisms for CTD-2116N20.1 and RP11-538D16.2. The CISH results confirmed that CTD-2116N20.1 and RP11-538D16.2 were correlated with a poor prognosis for HCC patients.
conclusionOur findings provide an independent and effective prognostic model to predict the survival rate of HCC patients. RP11-538D16.2 and CTD-2116N20.1 are highlighted as important exosome-related lncRNAs.
Indexed as
Identifiers
30018707PMC6038086W2901226235What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.